Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Stem Cells. Author manuscript; available in PMC 2010 June 25.
Published in final edited form as:
PMCID: PMC2892056

Concurrent blockade of α4-integrin and CXCR4 in hematopoietic stem/progenitor cell mobilization

CXCR4 antagonists, such as the small molecule inhibitor AMD3100, mobilize hematopoietic stem/progenitor cells (HSPC) with rapid kinetics, but rather low efficiency, when used alone.1 Mobilization with AMD3100 can be improved several-fold if it is administered as continuous infusion,2 but, in addition to being expensive, this approach may be no more practical than serial G-CSF injection. We have shown that, like AMD3100, blockade of the α4-integrin alone also results in HSPC mobilization in mice, macaques and humans. However, it is of marginally sufficient potency for single-modality mobilization.3;4 As intolerance or resistance to G-CSF may require alternative mobilization regimes, we tested the efficiency of mobilization by a combination of α4-integrin blockade and AMD3100 in macaques and mice. Treatment of a macaque with a 4 mg/kg bolus of AMD3100 increased circulating CD34+ cells from <1/μl to 14/μl within 6 hours (Fig. 1A, left panel). I.v. administration (5 mg/kg) of the anti-functional α4-integrin antibody previously used in humans (natalizumab),3 on its own mobilized 5 CD34+ cells/μl after 48 hours. However, with a subsequent s.c. injection of 4 mg/kg AMD3100 48 hours after the natalizumab treatment, 27 CD34+ cells/μl were in circulation 6 hours later (Fig. 1A, middle panel), i.e. mobilization with the two modalities together was more than additive. Circulating CFU-C were increased accordingly; the frequency of CFU-C among CD34+ cells was approximately 1:10 at all time points. We furthermore demonstrate that, similarly to what we recently showed in mice,2 continuous infusion of AMD3100 of a dose of 10 mg/kg*day resulted in progressive accumulation of markedly higher HSPC numbers than can be mobilized by single-bolus injection (23 CD34+ cells/μl), although peak values may not have been reached after three days (Fig. 1A right panel). To corroborate these observations and to alleviate concerns about off-target effects of anti-functional antibodies, we tested mobilization in a genetic model of α4 deficiency. AMD3100 was injected i.p. at a maximally effective dose of 4 mg/kg,2;5 or by continuous s.c. infusion of 40 mg/kg*day for 5 days.2 α4-deficient mice had the expected high numbers of circulating CFU-C at baseline.6 Injection (Fig. 1B) or infusion (Fig. 1C) of AMD3100 resulted in mobilization of significantly greater numbers of CFU-C in the α4-deficient mice (mobilization of 1,000 CFU-C/ml over baseline with bolus, of 35,000 CFU-C/ml over baseline in infusion-treated animals) than in WT animals (mobilization of 700 and 10,000 CFU-C/ml over baseline for bolus and infusion, respectively), i.e. as in the macaque, mobilization was at least additive. These data have implications from both a practical and a mechanistic standpoint. First, we demonstrate the efficient mobilization by combination of α4- and CXCR4-blockade. In this respect, small-molecule inhibitors of α4-integrin, which were recently tested in mice, thus hold some promise for future clinical studies.7 Second, our data suggest that blockade of α4-integrin and of CXCR4, molecules which were both shown to be important for homeostatic retention of HSPC, mobilize through independent molecular mechanisms. Although additive to synergistic mobilization was also described for treatment with G-CSF+AMD3100,2;5 the mechanism of the co-operative function in this case is not clear and likely a different one. Since the AMD3100 was administered at the end of a 5-day course of G-CSF, the benefit of that combination may rely on the expansion of the target population for AMD3100. In contrast, α4-integrin blockade is not associated with significant proliferation.

Figure 1
Mobilization by α4- and CXCR4-blockade


Funding: Deutsche Krebshilfe (HB), NIH (KHC: DK077864-02, HPK: HL53750, AI061839, HL53750, TP: HL58734)


Author contribution summary:

HB Conception and design, Financial support, Collection and/or assembly of data, Data analysis and interpretation, Manuscript writing, Final approval of manuscript

KLW Conception and design, Collection and/or assembly of data, Final approval of manuscript

KHC Collection and/or assembly of data, Final approval of manuscript

HPK Financial support, Provision of study material or patients, Final approval of manuscript

TP Conception and design, Financial support, Data analysis and interpretation, Manuscript writing, Final approval of manuscript

Reference List

1. Devine SM, Vij R, Rettig M, et al. Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood. 2008;112:990–998. [PubMed]
2. Bonig H, Chudziak D, Priestley G, et al. Insights into the biology of mobilized hematopoietic stem/progenitor cells (HSPC) through innovative treatment schedules of the CXCR4 antagonist AMD3100. Experimental Hematology. 2008 in press. [PMC free article] [PubMed]
3. Bonig H, Wundes A, Chang KH, et al. Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab. Blood. 2008;111:3439–3441. [PubMed]
4. Papayannopoulou T, Nakamoto B. Peripheralization of hemopoietic progenitors in primates treated with anti-VLA4 integrin. Proc Natl Acad Sci USA. 1993;90:9374–9378. [PubMed]
5. Broxmeyer HE, Orschell CM, Clapp DW, et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med. 2005;201:1307–1318. [PMC free article] [PubMed]
6. Scott LM, Priestley GV, Papayannopoulou T. Deletion of alpha4 integrins from adult hematopoietic cells reveals roles in homeostasis, regeneration, and homing. Mol Cell Biol. 2003;23:9349–9360. [PMC free article] [PubMed]
7. Ramirez PA, Holt M, Rettig MP, et al. Mobilization of normal mouse progenitors and acute promyelocytic leukemia (APL) cells with inhibitors of CXCR4 and VLA-4 in splenectomized and unsplenectomized mice. Blood. 2007;110(Suppl.1):2219.